Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.

Venkatraman N, Anagnostou N, Bliss C, Bowyer G, Wright D, Lövgren-Bengtsson K, Roberts R, Poulton I, Lawrie A, Ewer K, V S Hill A.

Vaccine. 2017 Oct 27;35(45):6208-6217. doi: 10.1016/j.vaccine.2017.09.028. Epub 2017 Sep 21.

PMID:
28941620
2.

Innate immune responses induced by the saponin adjuvant Matrix-M in specific pathogen free pigs.

Ahlberg V, Hjertner B, Wallgren P, Hellman S, Lövgren Bengtsson K, Fossum C.

Vet Res. 2017 May 22;48(1):30. doi: 10.1186/s13567-017-0437-2.

3.

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.

Cox F, Saeland E, Baart M, Koldijk M, Tolboom J, Dekking L, Koudstaal W, Lövgren Bengtsson K, Goudsmit J, Radošević K.

Virol J. 2015 Dec 8;12:210. doi: 10.1186/s12985-015-0435-9.

4.

A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice.

Koraka P, Bosch BJ, Cox M, Chubet R, Amerongen Gv, Lövgren-Bengtsson K, Martina BE, Roose J, Rottier PJ, Osterhaus AD.

Vaccine. 2014 Aug 6;32(36):4644-50. doi: 10.1016/j.vaccine.2014.06.058. Epub 2014 Jun 21.

PMID:
24962755
5.

Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.

Anderson J, Bréard E, Lövgren Bengtsson K, Grönvik KO, Zientara S, Valarcher JF, Hägglund S.

Clin Vaccine Immunol. 2014 Mar;21(3):443-52. doi: 10.1128/CVI.00776-13. Epub 2014 Jan 22.

6.

Early inflammatory response to the saponin adjuvant Matrix-M in the pig.

Fossum C, Hjertner B, Ahlberg V, Charerntantanakul W, McIntosh K, Fuxler L, Balagunaseelan N, Wallgren P, Lövgren Bengtsson K.

Vet Immunol Immunopathol. 2014 Mar 15;158(1-2):53-61. doi: 10.1016/j.vetimm.2013.07.007. Epub 2013 Aug 5.

PMID:
23988177
7.

Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.

Anderson J, Hägglund S, Bréard E, Comtet L, Lövgren Bengtsson K, Pringle J, Zientara S, Valarcher JF.

Clin Vaccine Immunol. 2013 Aug;20(8):1115-22. doi: 10.1128/CVI.00229-13. Epub 2013 May 29.

8.

Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen.

Reimer JM, Karlsson KH, Lövgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L.

PLoS One. 2012;7(7):e41451. doi: 10.1371/journal.pone.0041451. Epub 2012 Jul 23.

9.

Global transcriptional response to ISCOM-Matrix adjuvant at the site of administration and in the draining lymph node early after intramuscular injection in pigs.

Ahlberg V, Lövgren Bengtsson K, Wallgren P, Fossum C.

Dev Comp Immunol. 2012 Sep;38(1):17-26. doi: 10.1016/j.dci.2012.03.005. Epub 2012 Mar 15.

PMID:
22426325
10.

ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation.

Lövgren Bengtsson K, Morein B, Osterhaus AD.

Expert Rev Vaccines. 2011 Apr;10(4):401-3. doi: 10.1586/erv.11.25. Review. No abstract available.

PMID:
21506635
11.

An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model.

Azevedo MS, Gonzalez AM, Yuan L, Jeong KI, Iosef C, Van Nguyen T, Lovgren-Bengtsson K, Morein B, Saif LJ.

Clin Vaccine Immunol. 2010 Mar;17(3):420-8. doi: 10.1128/CVI.00395-09. Epub 2010 Jan 27.

12.

Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations.

Pinitkiatisakul S, Friedman M, Wikman M, Mattsson JG, Lövgren-Bengtsson K, Ståhl S, Lundén A.

Vaccine. 2007 May 4;25(18):3658-68. Epub 2007 Jan 24.

PMID:
17280751
13.

Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV.

Pahar B, Cantu MA, Zhao W, Kuroda MJ, Veazey RS, Montefiori DC, Clements JD, Aye PP, Lackner AA, Lovgren-Bengtsson K, Sestak K.

Vaccine. 2006 Nov 17;24(47-48):6839-49. Epub 2006 Jul 5.

PMID:
17050045
14.

Achieving directed immunostimulating complexes incorporation.

Wikman M, Friedman M, Pinitkiatisakul S, Andersson C, Lövgren-Bengtsson K, Lundén A, Ståhl S.

Expert Rev Vaccines. 2006 Jun;5(3):395-403. Review.

PMID:
16827623
15.

High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen.

Nguyen TV, Yuan L, Azevedo MS, Jeong KI, Gonzalez AM, Iosef C, Lovgren-Bengtsson K, Morein B, Lewis P, Saif LJ.

Clin Vaccine Immunol. 2006 Apr;13(4):475-85.

16.

Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine.

Nguyen TV, Yuan L, Azevedo MS, Jeong KI, Gonzalez AM, Iosef C, Lovgren-Bengtsson K, Morein B, Lewis P, Saif LJ.

Vaccine. 2006 Mar 20;24(13):2302-16. Epub 2005 Dec 1.

PMID:
16361002
17.

General strategies for efficient adjuvant incorporation of recombinant subunit immunogens.

Wikman M, Friedman M, Pinitkiatisakul S, Andersson C, Hemphill A, Lövgren-Bengtsson K, Lundén A, Ståhl S.

Vaccine. 2005 Mar 18;23(17-18):2331-5.

PMID:
15755622
18.

Applying biotin-streptavidin binding for iscom (immunostimulating complex) association of recombinant immunogens.

Wikman M, Friedman M, Pinitkiatisakul S, Hemphill A, Lövgren-Bengtsson K, Lundén A, Ståhl S.

Biotechnol Appl Biochem. 2005 Apr;41(Pt 2):163-74.

PMID:
15296488
19.

Identification of adjuvants that enhance the therapeutic antibody response to host IgE.

Johansson J, Ledin A, Vernersson M, Lövgren-Bengtsson K, Hellman L.

Vaccine. 2004 Jul 29;22(21-22):2873-80.

PMID:
15246623
20.

Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

González AM, Nguyen TV, Azevedo MS, Jeong K, Agarib F, Iosef C, Chang K, Lovgren-Bengtsson K, Morein B, Saif LJ.

Clin Exp Immunol. 2004 Mar;135(3):361-72.

21.

Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.

Davis D, Donners H, Willems B, Lövgren-Bengtsson K, Akerblom L, Vanham G, Barnett S, Morein B, Heeney JL, van der Groen G.

Vaccine. 2004 Jan 26;22(5-6):747-54.

PMID:
14741168
22.

Protection and antibody responses to oral priming by attenuated human rotavirus followed by oral boosting with 2/6-rotavirus-like particles with immunostimulating complexes in gnotobiotic pigs.

Nguyen TV, Iosef C, Jeong K, Kim Y, Chang KO, Lovgren-Bengtsson K, Morein B, Azevedo MS, Lewis P, Nielsen P, Yuan L, Saif LJ.

Vaccine. 2003 Sep 8;21(25-26):4059-70.

PMID:
12922143
23.

Influence of maternal immunity on antibody and T-cell response in mice.

Blomqvist GA, Lövgren-Bengtsson K, Morein B.

Vaccine. 2003 May 16;21(17-18):2022-31.

PMID:
12706692
24.

Immunostimulating complexes (ISCOMs) for nasal vaccination.

Hu KF, Lövgren-Bengtsson K, Morein B.

Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):149-59. Review.

PMID:
11516786
25.

In vivo and in vitro lipidation of recombinant immunogens for direct iscom incorporation.

Andersson C, Wikman M, Lövgren-Bengtsson K, Lundén A, Ståhl S.

J Immunol Methods. 2001 Sep 1;255(1-2):135-48.

PMID:
11470294
26.
27.

Impaired immunogenicity of immunostimulating complexes (iscoms) by administration in slow-release formulations.

Johansson M, Ranlund K, Lövgren-Bengtsson K.

Microbes Infect. 2000 Jul;2(9):1003-10.

PMID:
10967281
28.

Improved systems for hydrophobic tagging of recombinant immunogens for efficient iscom incorporation.

Andersson C, Sandberg L, Wernérus H, Johansson M, Lövgren-Bengtsson K, Ståhl S.

J Immunol Methods. 2000 Apr 21;238(1-2):181-93.

PMID:
10758248
29.

Iscoms with different quillaja saponin components differ in their immunomodulating activities.

Johansson M, Lövgren-Bengtsson K.

Vaccine. 1999 Jul 16;17(22):2894-900.

PMID:
10438061
30.

Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes.

Hu KF, Ekström J, Merza M, Lövgren-Bengtsson K, Morein B.

Med Microbiol Immunol. 1999 May;187(4):191-8.

PMID:
10363675
31.

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines.

Wilson AD, Lövgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ.

Vaccine. 1999 Mar 5;17(9-10):1282-90.

PMID:
10195641
32.

General expression vectors for production of hydrophobically tagged immunogens for direct iscom incorporation.

Andersson C, Sandberg L, Murby M, Sjölander A, Lövgren-Bengtsson K, Ståhl S.

J Immunol Methods. 1999 Jan 1;222(1-2):171-82.

PMID:
10022383
33.

ISCOM: a delivery system for neonates and for mucosal administration.

Morein B, Villacrés-Eriksson M, Ekström J, Hu K, Behboudi S, Lövgren-Bengtsson K.

Adv Vet Med. 1999;41:405-13. Review. No abstract available.

PMID:
9890031
34.

Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction.

Villacres MC, Behboudi S, Nikkila T, Lovgren-Bengtsson K, Morein B.

Cell Immunol. 1998 Apr 10;185(1):30-8.

PMID:
9636680
35.

Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes.

Sambhara S, Woods S, Arpino R, Kurichh A, Tamane A, Underdown B, Klein M, Lövgren Bengtsson K, Morein B, Burt D.

J Infect Dis. 1998 May;177(5):1266-74.

PMID:
9593011
36.

Kinetics, localization and characteristics of B- and T-cell responses to iscoms containing human influenza virus glycoproteins.

Johansson M, Lövgren-Bengtsson K, Sjölander A, Morein B.

Dev Biol Stand. 1998;92:289-94.

PMID:
9554283
37.

Iscom, a delivery system for parenteral and mucosal vaccination.

Morein B, Villacrés-Eriksson M, Lövgren-Bengtsson K.

Dev Biol Stand. 1998;92:33-9. Review.

PMID:
9554257
38.

A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen.

Davis D, Morein B, Akerblom L, Lövgren-Bengtsson K, van Gils ME, Bogers WM, Teeuwsen VJ, Heeney JL.

Vaccine. 1997 Oct;15(15):1661-9.

PMID:
9364697
39.

Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses.

Sjölander A, van't Land B, Lövgren Bengtsson K.

Cell Immunol. 1997 Apr 10;177(1):69-76.

PMID:
9140097
40.

Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines.

Rimmelzwaan GF, Baars M, van Beek R, van Amerongen G, Lövgren-Bengtsson K, Claas EC, Osterhaus AD.

J Gen Virol. 1997 Apr;78 ( Pt 4):757-65.

PMID:
9129647
41.

Iscoms in parasitological research.

Lundén A, Lövgren Bengtsson K, Sjölander A, Uggla A.

Parasitol Today. 1996 Aug;12(8):320-3.

PMID:
15275184
43.
44.

What to expect of future vaccines?

Morein B, Lövgren Bengtsson K, Villacres-Eriksson M.

Acta Vet Scand Suppl. 1996;90:101-6. Review. No abstract available.

PMID:
8996895

Supplemental Content

Loading ...
Support Center